The effect of vortioxetine on health-related quality of life in patients with major depressive disorder

Clinical Therapeutics
Ioana FloreaLinda Abetz-Webb

Abstract

Major depressive disorder (MDD) has detrimental effects on health-related quality of life (HRQoL). We describe the effect of vortioxetine on HRQoL in MDD patients by using patient-reported outcome instruments. HRQoL was evaluated in 5 short-term (6-8 weeks), randomized studies of vortioxetine (5-20 mg/d; n = 2155) versus placebo (n = 1316) in adults with MDD by using the 36-item Short-Form Health Survey (SF-36), the Quality of Life Enjoyment and Satisfaction Questionnaire-Short Form, the EuroQol 5-Dimension Questionnaire (EQ-5D), and the 12-item Health Status Questionnaire in 1 study in elderly patients. Only patients receiving the approved doses of vortioxetine 5, 10, 15, or 20 mg/d were included in the analysis. A random effects meta-analysis was performed on the 4 adult MDD studies that used the SF-36. A within-studies mixed model for repeated measures analysis based on the full analysis set (FAS) was used unless otherwise specified. Standardized effect size (SES) was calculated to reflect clinical relevance, based on a Cohen's d of 0.2. Vortioxetine produced significantly better results compared with placebo in the SF-36 mental component summary score (5 mg: 2.6, P = 0.001, SES of 0.22, n = 604; 10 mg: 4.8, P < 0.001, SES o...Continue Reading

References

Aug 18, 1989·JAMA : the Journal of the American Medical Association·K B WellsJ Ware
Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Jun 26, 1996·JAMA : the Journal of the American Medical Association·G E SimonE H Wagner
Oct 1, 1996·Archives of General Psychiatry·M OlfsonR Kathol
Jan 1, 1997·International Journal of Psychiatry in Medicine·A C LeonD V Sheehan
Aug 24, 1999·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·S L BishopJ Bucy
Sep 12, 2000·The Journal of Clinical Psychiatry·P A NewhouseC M Clary
Mar 7, 2001·The British Journal of Psychiatry : the Journal of Mental Science·M E ThaseR L Rudolph
Dec 26, 2001·JAMA : the Journal of the American Medical Association·K KroenkeM Weinberger
Dec 18, 2001·International Journal of Geriatric Psychiatry·T PettitA Bowling
Apr 3, 2002·The Journal of Clinical Psychiatry·Ondria C GleasonMichelle A Philipsen
Apr 29, 2003·The Journal of Clinical Psychiatry·Joseph R CalabreseKaren D Wagner
Jun 19, 2003·JAMA : the Journal of the American Medical Association·Ronald C KesslerUNKNOWN National Comorbidity Survey Replication
Jun 28, 2003·International Journal of Methods in Psychiatric Research·Philip S WangRonald C Kessler
Jul 2, 2003·The American Journal of Psychiatry·Lon S SchneiderUNKNOWN Sertraline Elderly Depression Study Group
Feb 6, 2004·General Hospital Psychiatry·George I PapakostasMaurizio Fava
May 5, 2004·The British Journal of Psychiatry : the Journal of Mental Science·T B UstünC J L Murray
Oct 20, 2004·The Journal of Clinical Psychiatry·Madhukar H TrivediCornelius D Pitts
Dec 14, 2004·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Michael J DetkeIstvan Bitter
Mar 24, 2005·Depression and Anxiety·A John Rush, Anjana Bose
Jun 14, 2005·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Eugene S PaykelTom Fryers
Jan 5, 2006·The American Journal of Psychiatry·Madhukar H TrivediUNKNOWN STAR*D Study Team
Jan 27, 2006·International Clinical Psychopharmacology·Stuart A Montgomery
Mar 17, 2006·The New England Journal of Medicine·Charles F ReynoldsDavid J Kupfer
Oct 26, 2006·The American Journal of Geriatric Pharmacotherapy·Somaia MohamedJohn Kasckow
May 4, 2007·The Journal of Clinical Psychiatry·Jean EndicottRalph W Swindle
Jun 26, 2007·International Journal of Clinical Practice·T N WiseJ Raskin
Jan 29, 2008·Current Psychiatry Reports·Diane WardenStephen R Wisniewski
Feb 28, 2008·International Clinical Psychopharmacology·Kathy Harnett Sheehan, David V Sheehan
Nov 26, 2008·The Journal of Clinical Psychiatry·Mark Hyman RapaportAlan Lipschitz
Dec 2, 2008·Psychiatry Research·Robert ArbuckleAlessio Degl' Innocenti
Jan 14, 2009·BMJ : British Medical Journal·Despina G Contopoulos-IoannidisJohn P A Ioannidis
Feb 13, 2009·Journal of Biopharmaceutical Statistics·Ohidul SiddiquiRobert O'Neill
May 19, 2009·Journal of Affective Disorders·Mascha C ten DoesschateUNKNOWN DELTA Study Group
Nov 7, 2009·Behavior Therapy·Deborah Roth LedleyDavid M Fresco
Dec 16, 2009·The Journal of Clinical Psychiatry·Madhukar H Trivedi

❮ Previous
Next ❯

Citations

Jul 27, 2018·Journal of Psychopharmacology·Michael Cronquist ChristensenDavid S Baldwin
Nov 21, 2018·Expert Opinion on Drug Discovery·Xenia GondaFrank I Tarazi
Jun 24, 2021·Perspectives in Psychiatric Care·Darawan WongprommateNahathai Wongpakaran

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.